#elevidys — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #elevidys, aggregated by home.social.
-
https://www.europesays.com/ch/62092/ Sarepta swings to Q1 2026 profit on Roche revenue #DuchenneMuscularDystrophy #Elevidys #NonGAAPNetIncome #Q12026Earnings #QuarterlyResults #Roche #RocheCollaboration #SareptaTherapeutics #SRPT
-
https://www.europesays.com/ch/51103/ Roche plots route to EMA approval for DMD gene therapy #BioWorld #ChugaiPharmaceuticalCoLtd #DuchenneMuscularDystrophy #Elevidys #EMA #Europe #GeneTherapy #JAPAN #Musculoskeletal #Regulatory #Roche #RocheAG #SareptaTherapeuticsInc
-
https://www.europesays.com/uk/570996/ Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information #AcuteLiverFailure #AmbulatoryPatients #DMDGene #DuchenneMuscularDystrophy #ELEVIDYS #Health #IntravenousInfusion #LiverInjury #Medication #PrescribingInformation #SareptaTherapeutics #UK #UnitedKingdom
-
Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information
CAMBRIDGE, Mass., November 14, 2025–(BUSINESS WIRE)–Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases,…
#NewsBeep #News #Medication #acuteliverfailure #ambulatorypatients #CA #Canada #DMDgene #duchennemusculardystrophy #ELEVIDYS #Health #intravenousinfusion #Liverinjury #prescribinginformation #sareptatherapeutics
https://www.newsbeep.com/ca/283661/ -
Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information
CAMBRIDGE, Mass., November 14, 2025–(BUSINESS WIRE)–Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for …
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Medication #acuteliverfailure #ambulatorypatients #DMDgene #duchennemusculardystrophy #ELEVIDYS #Health #intravenousinfusion #Liverinjury #prescribinginformation #SareptaTherapeutics
https://www.newsbeep.com/us/292160/ -
Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information
CAMBRIDGE, Mass., November 14, 2025–(BUSINESS WIRE)–Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for …
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Medication #acuteliverfailure #ambulatorypatients #DMDgene #duchennemusculardystrophy #ELEVIDYS #Health #intravenousinfusion #Liverinjury #prescribinginformation #SareptaTherapeutics
https://www.newsbeep.com/us/292160/ -
Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information
CAMBRIDGE, Mass., November 14, 2025–(BUSINESS WIRE)–Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases,…
#NewsBeep #News #Medication #acuteliverfailure #ambulatorypatients #DMDgene #duchennemusculardystrophy #ELEVIDYS #Health #intravenousinfusion #Liverinjury #prescribinginformation #sareptatherapeutics #UK #UnitedKingdom
https://www.newsbeep.com/uk/263365/ -
https://www.europesays.com/ie/181196/ Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information #AcuteLiverFailure #AmbulatoryPatients #DMDGene #DuchenneMuscularDystrophy #Éire #ELEVIDYS #Health #IE #IntravenousInfusion #Ireland #LiverInjury #Medication #PrescribingInformation #SareptaTherapeutics
-
Rústica e Caminhada da Integração arrecadam fundos para tratamento de menino com doença rara
-
Very disappointing news on the Duchenne muscular dystrophy front. Elevidys, the only available gene therapy for DMD has shown no significant improvement in motor function in kids receiving the treatment after 1 year. However, certain secondary outcomes showed some benefit.
It remains to be seen if FDA will allow it to stay on the market in the US, given that there are no other available treatments for DMD.
https://www.ajmc.com/view/sarepta-joins-pfizer-in-dmd-gene-therapy-trial-failures
#Duchenne #musculardystrophy #raredisease #genetherapy #elevidys #biotech #pharma
-
Very disappointing news on the Duchenne muscular dystrophy front. Elevidys, the only available gene therapy for DMD has shown no significant improvement in motor function in kids receiving the treatment after 1 year. However, certain secondary outcomes showed some benefit.
It remains to be seen if FDA will allow it to stay on the market in the US, given that there are no other available treatments for DMD.
https://www.ajmc.com/view/sarepta-joins-pfizer-in-dmd-gene-therapy-trial-failures
#Duchenne #musculardystrophy #raredisease #genetherapy #elevidys #biotech #pharma
-
Top FDA official overrules staff to approve gene therapy that failed trial - Enlarge / Dr. Peter Marks, Director of the Center for Biologics Evaluat... - https://arstechnica.com/?p=2032919 #duchennemusculardystrophy #clinicaltrials #clinicaldata #fdaapproval #genetherapy #petermarks #elevidys #science #sarepta #fda
-
Top FDA official overrules staff to approve gene therapy that failed trial - Enlarge / Dr. Peter Marks, Director of the Center for Biologics Evaluat... - https://arstechnica.com/?p=2032919 #duchennemusculardystrophy #clinicaltrials #clinicaldata #fdaapproval #genetherapy #petermarks #elevidys #science #sarepta #fda
-
Top FDA official overrules staff to approve gene therapy that failed trial - Enlarge / Dr. Peter Marks, Director of the Center for Biologics Evaluat... - https://arstechnica.com/?p=2032919 #duchennemusculardystrophy #clinicaltrials #clinicaldata #fdaapproval #genetherapy #petermarks #elevidys #science #sarepta #fda
-
Top FDA official overrules staff to approve gene therapy that failed trial - Enlarge / Dr. Peter Marks, Director of the Center for Biologics Evaluat... - https://arstechnica.com/?p=2032919 #duchennemusculardystrophy #clinicaltrials #clinicaldata #fdaapproval #genetherapy #petermarks #elevidys #science #sarepta #fda
-
Top FDA official overrules staff to approve gene therapy that failed trial - Enlarge / Dr. Peter Marks, Director of the Center for Biologics Evaluat... - https://arstechnica.com/?p=2032919 #duchennemusculardystrophy #clinicaltrials #clinicaldata #fdaapproval #genetherapy #petermarks #elevidys #science #sarepta #fda
-
Duchenne muscular dystrophy moms take comfort in the idea that #Elevidys means future DMD parents won't have the stark prognosis they did:
"There’s no treatment, take them home, love them, come back when they need wheelchairs."
today's cry, via @STAT's Jason Mast:
https://www.statnews.com/2023/06/30/duchenne-muscular-dystrophy-elevidys-sarepta-advocates/ -
Duchenne muscular dystrophy moms take comfort in the idea that #Elevidys means future DMD parents won't have the stark prognosis they did:
"There’s no treatment, take them home, love them, come back when they need wheelchairs."
today's cry, via @STAT's Jason Mast:
https://www.statnews.com/2023/06/30/duchenne-muscular-dystrophy-elevidys-sarepta-advocates/ -
Duchenne muscular dystrophy moms take comfort in the idea that #Elevidys means future DMD parents won't have the stark prognosis they did:
"There’s no treatment, take them home, love them, come back when they need wheelchairs."
today's cry, via @STAT's Jason Mast:
https://www.statnews.com/2023/06/30/duchenne-muscular-dystrophy-elevidys-sarepta-advocates/ -
Duchenne muscular dystrophy moms take comfort in the idea that #Elevidys means future DMD parents won't have the stark prognosis they did:
"There’s no treatment, take them home, love them, come back when they need wheelchairs."
today's cry, via @STAT's Jason Mast:
https://www.statnews.com/2023/06/30/duchenne-muscular-dystrophy-elevidys-sarepta-advocates/ -
Duchenne muscular dystrophy moms take comfort in the idea that #Elevidys means future DMD parents won't have the stark prognosis they did:
"There’s no treatment, take them home, love them, come back when they need wheelchairs."
today's cry, via @STAT's Jason Mast:
https://www.statnews.com/2023/06/30/duchenne-muscular-dystrophy-elevidys-sarepta-advocates/